Drug
Imatinib clinical trials
Also written Gleevec, Glivec, STI571 and CGP 57148.
- studies test it
- 408
- open now
- 29
- in phase 3
- 48
- first study started
- 1993
Keep track of what changes. Save the imatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
- Glivec
- 76
Studies by the year they started
407 studies that test it; most in 2002 (44)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1999 | 3 |
| 2000 | 10 |
| 2001 | 21 |
| 2002 | 44 |
| 2003 | 32 |
| 2004 | 44 |
| 2005 | 29 |
| 2006 | 33 |
| 2007 | 26 |
| 2008 | 17 |
| 2009 | 15 |
| 2010 | 11 |
| 2011 | 10 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 13 |
| 2015 | 7 |
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 7 |
| 2019 | 7 |
| 2020 | 14 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 106
- Phase 2
- 275
- Phase 3
- 48
- Phase 4
- 17
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 75 · Other 333
Novartis Pharmaceuticals (47) · National Cancer Institute (NCI) (38) · M.D. Anderson Cancer Center (28) · Asan Medical Center (8) · Novartis (8) · OHSU Knight Cancer Institute (6) · University of Bologna (6) · Memorial Sloan Kettering Cancer Center (5)
Often tested with
Tested in the same studies.
Dasatinib (21) · Nilotinib (20) · Cytarabine (13) · Docetaxel (13) · Gemcitabine (10) · Everolimus (8) · Capecitabine (7) · Cisplatin (7)
Studies
Open first, then newest update. How each study uses imatinib is read from its arms, and is right about nine times in ten.
Testing it · 408
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Imatinib
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingPhase 3GlaxoSmithKlineNCT07585266Written as Imatinib
- Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyRecruitingPhase 1National Cancer Institute (NCI)NCT06090669Written as imatinib
- Imatinib TDM in GISTRecruitingPhase 2Reema A. PatelNCT05493215Written as Imatinib
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingPhase 2University of California, San FranciscoNCT04598009Written as Imatinib
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingPhase 3Mats HeymanNCT04307576Written as Imatinib
- KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)RecruitingPhase 2Kumquat Biosciences Inc.NCT07406633Written as Imatinib (Gleevec)
- Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar PustulosisNot yet recruitingPhase 3Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07530367Written as Imatinib
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Imatinib
- Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaRecruitingPhase 2Victoria Biomedical Research InstituteNCT07559370Written as Artemether Lumefantrine and Imatinib Mesylate
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingPhase 1University of California, San DiegoNCT07171203Written as Imatinib
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingPhase 1Kura Oncology, Inc.NCT06655246Written as imatinib mesylate
- Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)RecruitingPhase 1Columbia UniversityNCT06889168Written as Imatimib Mesylate
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingPhase 2Asan Medical CenterNCT05385549Written as Imatinib Mesylate
- Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)RecruitingNot applicableVastra Gotaland RegionNCT05722795Written as Imatinib 400 MG Oral Tablet
- Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingPhase 1China Medical University HospitalNCT06962254Written as Imatinib
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingPhase 2Goethe UniversityNCT06061094Written as Imatinib
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingPhase 4Wei ZhaoNCT03844360Written as Imatinib
- Precision Cancer Therapy in Rare CancersRecruitingPhase 2Oslo University HospitalNCT06119789Written as Imatinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Imatinib 400 MG
See all 408 studies that test imatinib →
Given in every arm · 31 — imatinib is usual care beside what is tested
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingPhase 2Medical College of WisconsinNCT04838041Written as Imatinib
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNot yet recruitingPhase 2The University of Hong KongNCT07493408Written as Imatinib
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT02611492Written as Imatinib
- A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsActive, not recruitingPhase 2Centre Leon BerardNCT05152472Written as Imatinib 400 MG
- Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination TherapyActive, not recruitingPhase 2Obafemi Awolowo UniversityNCT07022743Written as Imatinib
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaActive, not recruitingPhase 3Children's Oncology GroupNCT03007147Written as Imatinib Mesylate
- Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingPhase 2University of JenaNCT03906292Written as Imatinib
- Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CMLTerminatedPhase 3Sarit AssoulineNCT05413915Written as Imatinib
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingPhase 2SWOG Cancer Research NetworkNCT03654768Written as Imatinib
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedPhase 1M.D. Anderson Cancer CenterNCT01751425Written as Imatinib Mesylate
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedPhase 1Novartis PharmaceuticalsNCT02081378Written as Imatinib
- A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic MalignanciesCompletedPhase 1Sumitomo Pharma America, Inc.NCT02352558Written as Imatinib
- A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and RifabutinCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03891901Written as Imatinib
- A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Active, not recruitingPhase 2Australasian Gastro-Intestinal Trials GroupNCT02365441Written as imatinib
- Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaTerminatedPhase 2OHSU Knight Cancer InstituteNCT01005914Written as imatinib mesylate
- Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT01319981Written as Imatinib
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedPhase 2University of WashingtonNCT03023046Written as Imatinib Mesylate
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic LeukemiaCompletedPhase 1/2National Cancer Institute (NCI)NCT00061945Written as imatinib mesylate
- A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST PatientsCompletedPhase 1Novartis PharmaceuticalsNCT01468688Written as STI571
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnPhase 2University of WashingtonNCT02538926Written as Imatinib Mesylate
Showing 20 of 31.
As the comparator · 35 — what is tested is compared with imatinib
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07885293Written as Imatinib
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06682169Written as Imatinib
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingPhase 4Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05367765Written as Imatinib
- Study in Adult Ph-positive ALLNot yet recruitingPhase 2Cardiff UniversityNCT04688983Written as Imatinib
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingPhase 3Il-Yang Pharm. Co., Ltd.NCT03722420Written as Imatinib
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Imatinib
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Imatinib
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 3TakedaNCT03589326Written as Imatinib
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedPhase 3Incyte CorporationNCT03112603Written as Imatinib
- Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT05071482Written as Imatinib
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04722848Written as Chemotherapy + Imatinib
- Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)WithdrawnPhase 2MedPacto, Inc.NCT06219733Written as Imatinib
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)TerminatedPhase 3AB ScienceNCT00812240Written as Imatinib
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedPhase 3PfizerNCT02130557Written as Imatinib
- A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedPhase 3Novartis PharmaceuticalsNCT02272777Written as Imatinib
- Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLCompletedPhase 3PfizerNCT00574873Written as imatinib
- Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML PatientsStatus unknownPhase 3First Affiliated Hospital of Harbin Medical UniversityNCT03515018Written as Imatinib
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaCompletedPhase 3Newcastle UniversityNCT01460693Written as Imatinib
- The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLCompletedPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT02204644Written as Imatinib 400mg qd
- Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedPhase 2Norwegian University of Science and TechnologyNCT00852566Written as Imatinib
Showing 20 of 35.
Codes
What other systems call imatinib · ClinicalTrials.gg INT006552
- MeSH (NLM) D000068877Imatinib MesylateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BKJ8M8G5HIIMATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 282388Confirmed FDA, Wikidata
- Wikidata Q177094imatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62035ImatinibOne source FDA
- DrugBank DB00619One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068877 | Imatinib Mesylate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BKJ8M8G5HI | IMATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 282388 | — | Confirmed FDA, Wikidata |
| Wikidata | Q177094 | imatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62035 | Imatinib | One source FDA |
| DrugBank | DB00619 | — | One source Wikidata |
Also registered as imatinib mesylate (UNII 8A1O1M485B · RxNorm 284924).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.